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known phenomenon, cases of three or more episodes are
scarce, especially in Europe.1,2 No association between KD
and vaccinations has been established to date.
A 4-year-old boy of Caucasian origin with a past history
of four episodes of tonsillitis and a family history of KD (his
older sister had the disease at the age of 3 years) was
admitted to our department fulfilling all clinical criteria for
KD, i.e., 5 days of fever, rash, erythema of the oral mucosa,
swelling and redness of the hands and feet, conjunctival
injection, and lymphadenopathy. After treatment with
intravenous g-globulin (IVIG) and high-dosage acetylsali-
cylic acid, the patient recovered fully with no sequelae at
the cardiologic follow up. Five months later, the patient
again presented with full-blown clinical manifestations of
KD. He received standard treatment, the symptoms cleared
up but an aneurismal dilatation of the right coronary artery
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he received the polysaccharide pneumococcal vaccine
(Pneumo 23) vaccination. After the administration of
standard treatment, we observed a complete recovery with
no long-term sequelae.
Multiple recurrences of KDare rare. During a 2-year period
0.2% of KD patients in Japan suffered at least two re-
currences.2 Younger age (<3 years), cardiac sequelae and/or
IVIG treatment at first incidence, male sex, and parental
history of the disease are possible risk factors for recurrent
KD.1 At the time of the first episode of KD, our patient was
older than 3 years and no cardiac sequelae were observed.
Nevertheless, his male sex, family history of KD, and treat-
ment with IVIG might have increased the risk of recurrence,
which increased further after the second KD episode. Most
secondary cases among family members appear within 7e10
days after the first case suggesting simultaneous exposure to
an unknown trigger. The occurrence of KD in our patient and
his sister was noncontemporaneous, indicating a possible
hereditary predisposition.
The third episode of KD in our patient started 3 days
after the administration of the Pneumo 23 vaccination. To
our knowledge no studies evaluating the association be-
tween KD and Pneumo 23 have been published. A review of
KD reports to the Vaccine Adverse Event Reporting System
between 1990 and 2007 did not show increased KD risk forby Elsevier Taiwan LLC. This is an open access article under the
/4.0/).
886 B. Kraszewska-Głomba et al.Prevnar, RotaTeq, or Pediatrix.3 In a postlicensure obser-
vational database safety study no association between KD
and the conjugate pneumococcal vaccine (PCV7) was
found.4 In addition, the authors of a postlicensure safety
surveillance study for PCV13 did not find a significantly
increased risk of KD following PCV13.5
Three episodes and a family history of KD in the case
presented support the hypothesis of the role of genetic
factors in the disease’s pathogenesis. Children with a his-
tory of recurrent KD are at high risk of another episode and
require greater clinical monitoring. Casual association be-
tween the Pneumo 23 vaccination and the third KD episode
in our patient is doubtful but provides a potential warning
that might deserve further investigation.
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